September 29, 2009
Acrux announced positive results from its Phase 3 trial of Axiron (testosterone topical solution 2%) for the treatment of testosterone deficiency (hypogonadism).
May 07, 2009
The FDA has announced that it will require a boxed warning to be included on the product labeling for two prescription topical testosterone gel products, AndroGel (testosterone 1%, from Solvay Pharmaceuticals) and Testim (testosterone 1%, from Auxilium Pharmaceuticals).
March 12, 2009
Endo Pharmaceuticals and Indevus Pharmaceuticals have announced that the FDA has accepted for review their complete response submission to the new drug application (NDA) for Nebido (testosterone undecanoate).
March 16, 2010
Quinnova announced the launch of Neosalus Cream, a non-steroidal anti-inflammatory cream for the treatment of various dermatoses (eg, atopic dermatitis, contact dermatitis, and hand eczema).
March 15, 2010
The FDA has notified healthcare professionals and patients that a Boxed Warning has been added to the Plavix (clopidogrel tablets, from Bristol-Myers Squibb and Sanofi) Prescribing Information to include information about reduced Plavix efficacy in patients who are poor metabolizers of Plavix.